Continuous Glucose Monitoring and Automated Insulin Delivery in Infants with Type 1 Diabetes: Real-World Evidence to Support Future International Guidelines
Authors' conclusion
Use of CGM is safe in very young children, with AID systems proving superior to traditional therapy.
Study context
- Population
- Children diagnosed with antibody-positive T1D before age 2
- Participants
- 76 children
- Exposure
- Automated insulin delivery (AID) vs multiple daily injections (MDI)/SAP
- AIDn = 47
- MDI/SAPn = 29reference
- Outcome
- TIR
- Follow-up
- 12 months
Methodological detailsmulticentre (13 centers), real-world
- Multicentre (13 centers)
- Real-world
Main finding
As reported in the abstract
P = 0.041
Observational data: associations, not effects.
Further findings
Time in tight range (TITR) · 12 months
P = 0.038
HbA1c · 12 months
- In multivariable regression, AID was the sole independent predictor of lower HbA1c
- P = 0.035
Continuous glucose monitoring (CGM) wear time
- CGM median wear time
- 97.0% (93.3; 98.1)
Safety
| Outcome | AID | MDI/SAP |
|---|---|---|
| Severe hypoglycemia (SH) · 12 months | 0 events | 7.1% |
Original publication
Continuous Glucose Monitoring and Automated Insulin Delivery in Infants with Type 1 Diabetes: Real-World Evidence to Support Future International Guidelines. Diabetes Technol Ther. Published 18 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →